NEW YORK (GenomeWeb News) – Theradiag today announced that Oséo has provided it €1.2 million ($1.6 million) to develop new diagnostic kits as part the French firm's participation in a project to develop RNA-targeting therapeutics and diagnostics aimed at HIV/AIDS and obesity.

Oséo, the French Agency for Innovation, is providing funding to Theradiag for work that will be done as part of its participation in CaReNA, a collaboration among drug development firm Splicos, Theradiag, and the French National Center for Research and Science.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.